SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (DXCM) (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the FDA has cleared the Dexcom G7 15 Day Continuous Glucose Monitoring System ...
FDA clears Dexcom G7 15-Day CGM for adults, offering 15.5 days of wear and a MARD of 8.0% for improved diabetes management. New features include Apple Watch connectivity, medication logging, and ...
Cardiometabolic digital diagnostics company Nanowear announced a licensing and data partnership with glucose monitoring specialist Dexcom to integrate glucose data from the Dexcom G7 into its ...
Smart ring giant Oura and Dexcom, a lead in glucose monitoring have collaborated for a big partnership. Together, they've announced a game-changing partnership, which will let users gain deeper ...
DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset, but management are optimistic about rebuilding BME sales channel. DexCom's newest G7 CGM competes closely ...
The U.S. Food and Drug Administration approved DexCom, Inc.’s (NASDAQ:DXCM) Dexcom G7 15-Day Continuous Glucose Monitoring System for people over 18 with diabetes. With an overall Mean Absolute ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback